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Introduction
Polycystic ovary syndrome (PCOS) is one of the most
common reasons of menstrual disorders and infertility
in women. According to different sources it can be
observed in 5-8 % of women of reproductive age [1,2].
At present, PCOS is diagnosed on the basis of Rotter-
dam Sponsored Consensus Workshop Group criteria
established at the conference of European Society for
Human Reproduction and Embryology and American
Society for Reproductive Medicine (ESHRE/ASRM)
in 2003 [3]. In order to diagnose polycystic ovary syn-
drome, 2 of the following symptoms must occur: rare
or no ovulation, hyperandrogenism – either clinical one
or that revealed in laboratory tests, or the ultrasound
picture of polycystic ovaries. At the same time, other
reasons for hyperandrogenism should be excluded.
It is accepted that PCOS is a genetic disease, and
yet an influence of environmental and hormonal fac-
tors is also taken into consideration [4,5]. Clinical
symptoms observed in polycystic ovary syndrome are
mainly: menstrual disorders (oligomenorrhoea), infer-
tility resulting from chronic anovulation, hirsutism,
acne, seborrhea and obesity concerning 35 – 60% of
patients. Ultrasonographic scanning reveals enlarged
ovaries greater than 10cm3 with multiple small antral
follicles and hormonal tests show increased androgen
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Abstract: Polycystic ovary syndrome (PCOS) is an endocrinological and metabolic disorder which may concern about 3-8
% of women. Some PCOS women have the increased leptin concentration in blood serum. Leptin concentration is higher in
patients with high body mass index (BMI) and impaired tissue sensitivity to insulin.  The aim of this study was to determine
leptin concentrations in PCOS patients before and after metformin treatment depending on BMI, insulin resistance calcu-
lated on the basis of the Homeostasis Model Assessment (HOMA) index, as well as concentrations of androgens: testos-
terone and androstendion. Such values as BMI, insulin resistance according to the HOMA index, and concentrations of
androstendion, testosterone and leptin were determined in 35 patients with PCOS before and after 3-month metformin treat-
ment administered in daily doses of 2 x 850 mg. Increased leptin levels before the therapy were observed in 91.3 % (21 out
of 23) of obese patients, in 75% (9 out of 12) non-obese patients, in 100% (8 patients) insulin resistance women, in 81.5%
(22 out of 27) insulin sensitive patients, in 94.7 % (18 out of 19) women with elevated androstendion concentration and in
75% (12 out of 16) with normal androstendion concentration, in 93.7% (15 out of 16) patients with increased testosterone
concentration and in 78.9% (15 out of 19) patients with testosterone concentrations within the normal range. After treatment
statistically significant decrease in leptin concentration was obtained in the patients with BMI≤25, insulin-sensitive patients
(HOMA<3.8) and patients whose testosterone and androstendion concentrations stayed within normal limits. Increased lep-
tin concentrations may be one of the elements of PCOS clinical picture. Metformin treatment considerably reduces leptin
concentration, if it is employed in non-obese PCOS patients, patients with normal an-drogen concentrations and those who
not have an impaired glucose tolerance. 
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concentrations. Hyperandrogenism in PCOS is the
consequence of greater than normal activity of theca
cells chronically stimulated by acyclically secreted
luteinizing hormone (LH) . Relative follicle-stimulat-
ing hormone (FSH) deficiency, in turn, results in
anovulation [5,6].
Apart from clinical and ultrasonographic symptoms
as well as hormonal irregularities which are necessary
to diagnose PCOS, there are also metabolic distur-
bances observed in some patients. Hyperinsulinemia
resulting from tissue insulin resistance is found in 50
% of patients with PCOS. If not treated, such disorders
may lead to the development of type 2 diabetes in the
future. It is therefore so important that all patients sus-
pected of PCOS undergo a 75 g oral glucose tolerance
test (OGTT) and have insulin concentrations deter-
mined so as carbohydrate metabolism disorders could
be assessed [7,8]. 
According to latest recommendations of  Androgen
Excess Society (AES) all patients with PCOS, regard-
less of BMI, should undergo a 75 g oral glucose toler-
ance test. It is necessary to repeat this test after 2 years
or frequently if there are any others risk factors of dia-
betes mellitus or every year if there are any symptoms
of impaired glucose tolerance in 75 g oral glucose tol-
erance test [9]. 
Some authors report on increased serum leptin con-
centration in PCOS patients [1,2,10-12]. Leptin is a
hormone produced predominantly in adipocytes. Pres-
ence of leptin receptors was observed in hypothala-
mus, liver, skeletal muscles, myocardium, ovaries, tes-
ticles, kidneys and adipose tissue [13]. The role of lep-
tin in an organism has not been fully explained so far.
It is assumed that it is involved in the regulation of
appetite, pubescence and fat metabolism. After bind-
ing leptin to hypothalamus receptors, production and
secretion of neuropeptide Y, responsible for appetite
stimulation, become inhibited [14,15]. Leptin concen-
tration in blood is directly proportional to BMI, but it
also depends on tissue sensitivity to insulin. It is con-
siderably higher in overweight and insulin-resistant
people, than in individuals with proper body mass and
normal sensitivity to insulin [16,17].
It is possible that leptin is an element linking mech-
anisms of energy balance with individual and sexual
development. The situation when energetic resources
of an organism diminish is a signal to increase food
intake, and also to reduce fertility requiring consider-
able energy expenditure. Nevertheless, obese women
whose leptin concentrations are high, often suffer from
ovulatory disorders and infertility as well [18].
In case of women with PCOS and obesity, certain
results suggest higher leptin concentration than it
could be expected concerning BMI [19-22]. Perhaps in
these cases, leptin can affect fertility through disturb-
ing central hormonal regulation, which is mainly relat-
ed to the correlation between leptin, neuropeptide Y
and LH, and indirectly also ovulation [18]. 
In people with the diagnosed impaired glucose tol-
erance and insulin resistance, it is justifiable to employ
medicines which sensitize tissues to insulin. Patients
usually receive metformin, an oral agent belonging to
the biguanide group, which not only improves insulin
sensitivity but also indirectly positively affects
ovaries. About 40% of non-ovulating patients start to
ovulate naturally [23,26]. It is also believed that met-
formin therapy significantly reduces leptin con-centra-
tion both in obese and slim women [23,26-28].
The aim of this study was to assess leptin concen-
trations in the patients with the diagnosed polycystic
ovary syndrome before and after metformin treatment
depending on BMI, insulin resistance calculated on the
basis of the Homeostasis Model Assesment (HOMA)
index, as well as concentrations of androgens: testos-
terone and androstendion.
Material and methods
Patients. The research involved 35 patients with polycystic ovary
syndrome diagnosed on the basis of Rotterdam criteria and treated in
Department of Reproduction and Gynecology, Pomeranian Medical
University. All the patients were carefully interviewed and informa-
tion concerning menstrual disorders and fertility were collected.
During the clinical examination, body mass and height were meas-
ured. On the basis of the obtained results, BMI (body mass index –
the ratio of body mass in kg to the height in m raised to the second
power) was calculated. The following normal ranges for BMI were
accepted: ≤25 – normal weight; >25 – overweight and obesity. Ultra-
sonographic examination of the reproductive organ was carried out
using a 3.5 MHz intravaginal probe, Toshiba Tosbee. 
Study protocol. After evaluation of liver and kidney activity (the
concentrations of AspAT, AlAT, urea and creatinine were deter-
mined), patients were classified for the 3-month met-formin treat-
ment administered in daily doses of 2 x 850 mg. Criteria excluding
patients from the examination were: hypersensitivity to metformin,
heart disease, hypertension, anaemia, increased serum concentra-
tions of aminotransferases (norm: AST 10-31 U/L, ALT <36.4
U/L), and elevated serum concentrations of urea and/or creatinine
(norm: urea 17-34 mUg/dl, creatinine: 0.66-1.09 mg/dl), alco-
holism and type 1 or type 2 diabetes. After this period of therapy,
the women underwent all examinations performed at the beginning
of treatment. Both before and after treatment, patients were divid-
ed into 2 groups: with BMI >25 and ≤25; next the presence or lack
of insulin resistance was determined in each patient by means of
the HOMA index. Serum concentrations of testosterone, andros-
tendion and fasting leptin were analysed in each patient. 
Hormone concentration. Concentrations of hormones, namely
androstendion (normal range: 0.5-3.5 ng/ml), testosterone (normal
range: 0.06-0.82 ng/ml), FSH, LH, prolactin (PRL) and fasting lep-
tin concentration were determined in blood serum. Leptin concen-
tration <8.2 ng/ml was accepted as normal – according to the local
laboratory kit used to assess leptin concentration. All hormonal
tests were performed in the fasted status (last meal at 6 pm on the
day before the test) between 3rd and 5th day of menstrual period. 
Oral glucose tolerance test. Additionally, in order to diagnose
metabolic disorders, the patients were subjected to a 75 g oral glu-
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cose tolerance test, during which concentrations of fasting glucose
and insulin were determined and after 120 minutes from glucose
administration. Using the obtained values of glucose and insulin
concentrations, the Homeostasis Model Assesment (HOMA) index
for insulin resistance assessment was calculated. Insulin resistance
was diagnosed when it is ≥3.8 [29].
All blood tests were performed in Central Laboratory of
Autonomous Public Clinical Hospital No. 1 of Pomeranian Medi-
cal University in Szczecin. To testosteron, androstendion, glucose
and insulin concentrations assessments Roche laboratory kits were
used. Glucose concentrations were evaluated by enzymatic method
with hexokinase on Cobas Integra 400. Testosteron, androstendion
and insulin concentrations were evaluated with electrochemolumi-
nescence metod (ECL) on Cobas e601. Leptin concentrations were
evaluate by enzyme-linked immunosorbent assay method (ELISA)
with Biowender kit.
Statistical analysis. Statistical analysis was performed using Sta-
tistica 6.0. The t-student test was used in case of normally distrib-
uted values, and in other case the Wilcoxon-Cox rank test was
applied. p<0.05 was accepted as statistically significant.
Results
From among all the patients with the diagnosed poly-
cystic ovary syndrome, 30 women (85.7%) had the
increased leptin concentrations. Before treatment in
the group of 23 patients with BMI >25, the increased
leptin levels were found in 21 (91.3%) patients. The
mean leptin concentration in these women reduced
after metformin treatment but the observed fall was
not statistically significant. (Table 1). Before the
therapy, 9 (75%) out of 12 patients with BMI ≤25,
had the elevated leptin levels. During metformin
treatment, leptin concentration considerably
decreased in this group. (Table 2). In the group of 8
patients with insulin resistance determined by means
of the HOMA index, all the examined women had the
increased leptin concentrations before the therapy. In
this group the fall in leptin concentrations was noted
after treatment, but it was not statistically significant.
(Table 3). Conversely, in the group of 27 women with
normal insulin sensitivity, the increased leptin con-
centrations were observed in 22 (81.5%) patients and
the fall in leptin concentration in these women after
metformin treatment was statistically significant.
(Table 4).
Leptin concentrations were also analysed before
and after treatment in the patients with the increased
androstendion levels. In the group of 19 such women,
18 (94.7%) ones had leptin concentrations above nor-
mal range. In these women the fall in leptin concentra-
tion was observed, but it was not significant. (Table 5).
On the contrary, considerable fall was noted in those
women whose androstendion levels were within the
normal range at the moment of PCOS diagnosis. From
among 16 such patients, 12 (75%) ones had the
increased leptin concentration before the therapy
(Table 6).
In the group of 16 women with the increased testos-
terone concentration at the moment of diagnosis, 15
(93,7%) ones had the elevated leptin levels  before the
therapy. After metformin treatment insignificant fall in
leptin concentration was observed (Table 7). In the
group of 19 patients with testosterone concentration
within the normal range, hyperleptinemia was diag-
nosed in 15 (78.9%) ones and in these patients signifi-
cant fall in leptin concentrations after metformin treat-
ment  was observed (Table 8).
In this study we also analysed how leptin concen-
trations depend on BMI, the HOMA index and andro-
gen concentrations. The only group in which consider-
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Table 1. The changes and correlation between BMI and leptin con-
centration in the patients with BMI>25 before and after metformin
treatment (n=23).
Table 2. The changes and correlation between BMI and leptin con-
centration in the patients with BMI≤25 before and after metformin
treatment (n=12).
Table 3. The changes and correlation between the HOMA index
and leptin concentration in the patients with HOMA≥3.8 before
and after metformin treatment (n=8).
able correlation between leptin concentration and
body mass index was confirmed both before and after
treatment was the group of patients with BMI>25
(Table 1). Neither correlation was found between
BMI and leptin concentration in the group of patients
with BMI≤25, nor between insulin resistance
expressed by the HOMA index and leptin concentra-
tion in the group of patients with HOMA≥3.8 and
HOMA<3.8. No such correlation was found between
concentrations of testosterone and androstendion and
concentrations of leptin, which reefers both to the
group with increased concentrations of these hor-
mones, and the groups in which testosterone and
androstendion levels stayed within the normal range
(Tables 2-8).
Discussion
Polycystic ovary syndrome is a very heterogeneous
condition. The diagnostic criteria are clear, and yet
apart from menstrual disorders, hyperandrogenism –
either clinical one or that revealed in laboratory tests,
and the characteristic ultrasound picture of ovaries,
there is a number of other complaints, mainly
endocrinological and metabolic ones, which also
belong to the clinical picture of this disease. Some of
them are obesity and impaired glucose tolerance. It
was the fact which persuaded us to make an assump-
tion that increased concentration of leptin can be the
one of PCOS laboratory symptoms, as well as it can
play certain part in etiopathogenesis of this disease. It
is possible because of the influence of this hormone on
the production of ovarian hormones at the central
level: in hypothalamus and pituitary gland, as well as
due to the direct effect that it has on an ovary. In all
these structures the presence of leptin receptors was
confirmed [13,15,19,20]. 
Our study revealed that most patients with the diag-
nosed polycystic ovary syndrome had the elevated leptin
concentration. These irregularities were observed both in
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Table 4. The changes and correlation between the HOMA index
and leptin concentration in the patients with HOMA<3.8 before
and after metformin treatment (n=27).
Table 5. The changes and correlation between the concentrations
of androstendion (A) and leptin in the patients with the increased
androstendion concentration before and after metformin treatment
(n=19).
Table 6. The changes and correlation between concentrations of
androstendion (A) and leptin in the patients with androstendion
concentration within the normal range before and after metformin
treatment (n=16).
Table 7. The changes and correlation between concentrations of
testosterone (T) and leptin in the patients with the elevated testos-
terone concentration before and after metformin treatment (n=16).
Table 8. The changes and correlation between concentrations of
testosterone (T) and leptin in the patients with testosterone level
within the normal range before and after metformin treatment
(n=19).
the group of obese and overweight patients, and in slim
ones. Similar results were obtained while analysis of lep-
tin concentration in the patients with confirmed insulin
resistance – all the patients had hyperleptinemia. Also in
the group of women with PCOS and tissue insulin sensi-
tivity, the majority of patients had the increased leptin
concentrations in blood serum. It suggests that hyper-
leptinemia in PCOS does not only depend on increased
adipose tissue mass or insulin resistance.
Brzechffa et al. refer to the data which confirm that
patients with polycystic ovary syndrome have higher
leptin concentrations than it could be expected on the
basis of their BMI or insulin resistance [19]. Similar
results were reported by Panidis et al. who noticed that
patients with PCOS and insulin resistance have con-
siderably higher leptin concentrations, which means
that leptin can play a part in etiopathogenesis of this
syndrome [30]. Most authors confirm increased con-
centrations of leptin in blood of PCOS patients, but at
the same time, they emphasize a lack of explicit evi-
dence for its role in pathogenesis of this disease
[10,12,31]. In our study, significant correlation
between BMI and leptin concentrations was only
proved in the group of obese and overweight women
(BMI>25). Such results were reported by many other
authors, as well [32-34].
We also assessed concentrations of androgens and
leptin in PCOS patients. While analysing the groups of
patients with PCOS and increased and normal andro-
gen concentrations, we noticed the elevated leptin lev-
els in most patients in both these groups. In none of the
groups, however, we did manage to prove significant
correlation between concentration of leptin and con-
centrations of androstendion and testosterone. Thus,
influence of leptin on androgen concentrations in
patients with polycystic ovary syndrome has not been
ultimately confirmed. The literature gives different
data on that issue. Some authors claim that such rela-
tion does not exist [32,33]. Others, in turn, prove the
correlation between concentrations of leptin and
testosterone in PCOS [31].
In the presented study, we analysed how leptin con-
centration is affected by 3-month metformin treatment
administered in daily doses of 2 x 850 mg.  Metformin
is an agent which reduces insulin resistance, decreases
body mass index, and also, which is supported by many
authors,  causes the fall in leptin concentration in PCOS
patients. Zhao mentions data which confirm the lower-
ing of insulin concentrations measured in fasting status,
the decrease in leptin levels, and hormonal normaliza-
tion in women subjected to metformin treatment. More-
over, he noted that ovulation appeared naturally in these
women, and that they better reacted to stimulation of
ovulation after the therapy [27]. Also Kowalska et al.
proved the efficiency of metformin therapy in PCOS
patients. She noticed that metformin causes significant
decrease in the concentrations of testosterone, insulin
and leptin in obese PCOS patients [34]. In his research,
Pasquali et al. compared influence of metformin and
placebo on obese patients with PCOS. He confirmed
therapeutic effect of this medicine, namely normalisa-
tion of testosterone and leptin levels and reduction of
BMI [25]. In our study we observed that therapy with
this agent leads to the fall in leptin concentrations main-
ly in non-obese women, and also those without impaired
glucose tolerance. By contrast, it does not affect leptin
concentration in women with PCOS and BMI>25 or
patients with HOMA≥3.8. We found an evidence for the
significant decrease in androgen concentrations in the
patients treated with metformin, in whom these values
went beyond the normal range before the therapy. Met-
formin treatment caused the decrease in leptin concen-
trations, but only in patients who had normal androsten-
dion and testosterone concentrations at the moment of
diagnosis. 
The results may suggest that leptin fulfils an impor-
tant role in pathogenesis of PCOS, irrespective of
BMI, impaired glucose tolerance and hyperandro-
genism. Perhaps achieved effect of metformin treat-
ment also depends on the influence that it has on lep-
tin concentration.
To conclude, increased leptin concentrations may
be one of the elements of PCOS clinical picture and
metformin treatment considerably reduces leptin con-
centration, if it is employed in non-obese PCOS
patients, with normal androgen concentrations and do
not have an impaired glucose tolerance. 
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